Parkinson Agent Tavapadon Meets Primary and Secondary End …
WEB5 days ago · All told, tavapadon showed a safety profile that was consistent with previous observations, with a majority of the AEs being mild to moderate in severity. REFERENCES 1. AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease. …
AbbVie Announces Positive Topline Results from Phase 3 TEMPO …
WEB4 days ago · Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26; ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools ...
ABBV's Newly Added Parkinson's Disease Drug Meets Second …
WEB3 days ago · BVS. AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently acquired investigational drug tavapadon in adults with early Parkinson ...
News
WEB5 days ago · Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease. The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy in adults with early Parkinson's disease.
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
WEB4 days ago · AbbVie inherited tavapadon in August 2023 after it acquired Cerevel Therapeutics in an $8.7bn deal. The drug candidate is being evaluated in four clinical trials, dubbed TEMPO-1 to 4. These ...
Cerevel Therapeutics Announces Positive Topline Results for ... - News
WEBApr 18, 2024 · Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks. Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for ...
Abbvie drug improves Parkinson's symptoms in trial - STAT
WEB5 days ago · Annual. $399. Save 15%. Get Started. View All Plans. AbbVie's Parkinson’s drug, tavapadon, which it got from Cerevel Therapeutics, alleviated symptoms in a Phase 3 trial.
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase …
WEB5 days ago · (RTTNews) - Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease.
AbbVie Parkinson's drug from $8.7B Cerevel buyout scores
WEB5 days ago · AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy. The pharma got ...
AbbVie Announces Positive Topline Results from Phase 3 TEMPO …
WEB5 days ago · NORTH CHICAGO, Ill., Sept. 26, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease.